Objective To analyze the safety and efficacy of low-profile visualized intraluminal support (LVIS) stent-assisted embolization for the anterior choroidal artery aneurysms. Methods The clinical and follow-up data of 31 patients with wide-necked anterior choroidal artery aneurysms who received LVIS stent-assisted embolization therapy in The Second Affiliated Hospital of Nanchang University from Jan. 2015 to Jan. 2019 were retrospectively analyzed. Cerebral digital subtraction angiography (DSA) and Raymond classification were used to evaluate the embolization effect, and modified Rankin scale (mRS) score was used to evaluate the prognosis. Results All the 31 patients with wide-necked anterior choroidal artery aneurysms (including 22 cases of ruptured aneurysms and 9 cases of non-ruptured aneurysms) were successfully treated with LVIS stent-assisted embolization. The results of DSA immediately after embolization showed that 25 aneurysms were presented with Raymond grade Ⅰ (complete occlusion), 4 with grade Ⅱ (subtotal occlusion) and 2 with grade Ⅲ (partial occlusion), parent arteries were unobstructed, and ischemic complications occurred in 4 cases. The results of DSA 6-9 months after embolization showed that 27 aneurysms were Raymond grade Ⅰ, 3 grade Ⅱ and 1 grade Ⅲ, 1 case had a mild stenosis of anterior choroidal artery, and no significant stenosis or occlusion was found in the remaining parent arteries. Twenty-nine patients had a good prognosis (mRS score ≤ 2), and 2 patients had a poor prognosis (mRS score was 3). There was no significant difference in postoperative ischemic complication incidence, complete occlusion rate or good prognosis rate 6-9 months after embolization between ruptured and non-ruptured groups (all P>0.05). No rebleeding or retreatment occured during follow-up. Conclusion LVIS stent-assisted embolization of wide-necked anterior choroidal artery aneurysms is safe and effective, showing no significant difference between ruptured and non-ruptured groups, however, it still needs to be further verified by multicenter trials with large samples and long-term follow-up.